Adaptive Biotechnologies Corp is at the forefront of harnessing the power of the immune system to improve disease diagnosis and treatment. With a focus on immune medicine, the company's innovative platform offers deep insights into the adaptive immune system, aiding in the development of clinical immunomics data. Its notable product, the clonoSEQ diagnostic test, plays a crucial role in detecting and monitoring cancer cells post-treatment. Adaptive Biotechnologies also engages in significant partnerships, including with Genentech and Microsoft, to advance its mission of transforming disease detection and therapy.